Understand the source comparison
Does KLOW Help Anti-Inflammatory Research: Study Design Comparison
The following table compares experimental approaches where KLOW peptide has been evaluated for anti-inflammatory effects, organized by inflammation model, measured outcomes, and observed effect sizes. LPS-Stimulated Macrophages (RAW 264.7) Lipopolysaccharide 1
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares experimental approaches where KLOW peptide has been evaluated for anti-inflammatory effects, organized by inflammation model, measured outcomes, and observed effect sizes.
- LPS-Stimulated Macrophages (RAW 264.7)
- Lipopolysaccharide 100 ng/mL
- 10–100 μM
- NF-κB translocation, TNF-α secretion, IL-6 secretion
- 30–45% reduction in NF-κB nuclear localization; 25–35% decrease in TNF-α
- Gold standard acute inflammation model; dose-response consistent across labs
- Renal UUO Fibrosis Model
- Surgical ureteral obstruction
- 0.5–1.0 mg/kg IP q48h × 14 days
- Tissue IL-1β mRNA, F4/80+ macrophage count, fibrosis score
- 50% reduction in IL-1β; 40% decrease in macrophage infiltration
- Chronic inflammation context; results align with klotho's known renoprotective role
- TNF-α Activated Endothelial Cells (HUVECs)
- Recombinant TNF-α 10 ng/mL
- 25–75 μM
- VCAM-1 and ICAM-1 surface expression by flow cytometry
- 35–40% reduction in adhesion molecule expression
- Clinically relevant to atherosclerosis research; lower doses effective than macrophage models
- LPS-Activated Microglia (BV-2)
- Lipopolysaccharide 500 ng/mL
- 50–100 μM
- Nitric oxide production, iNOS protein expression, IL-6 secretion
- 30–35% reduction in NO; 25% decrease in iNOS
- Smaller effect size than peripheral models; may reflect CNS-specific factors
- Collagen-Induced Arthritis Model
- Type II collagen immunization
- 1.0 mg/kg IP q48h × 21 days
- Joint swelling score, serum IL-6, histological inflammation score
- 20–30% reduction in joint swelling; 35% decrease in serum IL-6
- Systemic autoimmune inflammation; modest but measurable effects